Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years.

Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.

Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of ...

Nektar, which accused Lilly of making errors in its analysis of the data, forged ahead with the programme and started the ...

A focused update to AAD’s adult AD guidelines recommends tapinarof, roflumilast, lebrikizumab, and nemolizumab based on ...

Nektar reported positive Phase 2b trial data for rezpegaldesleukin in atopic dermatitis, showing strong efficacy and a ...

Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis. A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality.